Showing results (1-10 of 17) with videos related to
Sort By:
Pageof 2
Current Hematologic Malignancy Reports|January 11, 2016
Prognostic Factors for Chronic Lymphocytic LeukemiaChristopher Chen, Soham PuvvadaCancer Genetics|October 2, 2013
Molecular classification, pathway addiction, and therapeutic targeting in diffuse large B cell lymphomaSoham Puvvada, Samantha Kendrick, Lisa RimszaCurrent Treatment Options in Oncology|July 18, 2016
Limited Stage Aggressive Non-Hodgkin Lymphoma: What Is Optimal Therapy?Abhijeet Kumar, Srinath Sundararajan, Soham Puvvada, et al.Acta Haematologica|November 2, 2016
Outcome Comparison of Allogeneic versus Autologous Stem Cell Transplantation in Transformed Low-Grade Lymphoid Malignancies: A Systematic Review and Pooled Analysis of Comparative StudiesSeongseok Yun, Nicole D Vincelette, Ivo Abraham, et al.Case Reports in Hematology|December 6, 2014
A rare presentation of in situ mantle cell lymphoma and follicular lymphoma: a case report and review of the literatureJosephine Taverna, Anju Nair, Seongseok Yun, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2026
Post-Hoc Analysis of the Phase II DESTINY-PanTumor02 Study: Local and Central HER2 IHC Concordance and Trastuzumab Deruxtecan Efficacy by HER2 IHC Status in HER2-Expressing Solid TumorsVicky Makker, Jung-Yun Lee, Do-Youn Oh, et al.Critical Reviews in Oncology/Hematology|December 25, 2016
Brentuximab vedotin for treatment of non-Hodgkin lymphomas: A systematic reviewGarrett K Berger, Ali McBride, Stephanie Lawson, et al.British Journal of Clinical Pharmacology|November 19, 2016
Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphomaSuresh K Agarwal, Ahmed Hamed Salem, Alexey V Danilov, et al.Immunotherapy|October 4, 2017
Anti-CD 19 and anti-CD 20 CAR-modified T cells for B-cell malignancies: a systematic review and meta-analysisIrbaz Bin Riaz, Umar Zahid, Muhammad Umar Kamal, et al.Blood|November 15, 2014
Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313Daniel O Persky, Thomas P Miller, Joseph M Unger, et al.Pageof 2